Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
EU approves Sanofi's Dupixent for 'smoker's lungs'
01:11am, Wednesday, 03'rd Jul 2024
Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster th
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
01:00am, Wednesday, 03'rd Jul 2024
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two l
Sanofi eyes German insulin investment of up to $1.6 bln, source says
12:00pm, Monday, 01'st Jul 2024
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person famili
Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says
01:39am, Monday, 01'st Jul 2024
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin bra
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
09:00am, Sunday, 30'th Jun 2024
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from S
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
08:02am, Thursday, 27'th Jun 2024
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
02:00am, Thursday, 27'th Jun 2024
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 ag
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
05:30pm, Wednesday, 26'th Jun 2024
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixen
Sanofi-backed Formation Bio raises $372 million in late-stage funding round
12:47pm, Wednesday, 26'th Jun 2024
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
09:16am, Wednesday, 26'th Jun 2024
Sanofi SA SNY is calling for initial bids for its $20 billion consumer health division.
Press Release: Availability of the Q2 2024 Aide-mémoire
01:32pm, Tuesday, 25'th Jun 2024
Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sa
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee
03:30am, Friday, 21'st Jun 2024
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee Paris, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi F
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
01:00am, Friday, 21'st Jun 2024
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first
Belharra today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
01:00am, Monday, 17'th Jun 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that updated efficacy and safety
